Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2127-2133

  Van Diepen, Sean ^a,b   Newby, L Kristin ^a   Lopes, Renato D ^a   Stebbins, Amanda ^a   Hasselblad, Vic ^a   James, Stefan ^c   Roe, Matthew T ^a   Ezekowitz, Justin A ^b   Moliterno, David J ^d   Neumann, Franz Josef ^e   Reist, Craig ^a   Mahaffey, Kenneth W ^a   Hochman, Judith S ^f   Hamm, Christian W ^g   Armstrong, Paul W ^b   Granger, Christopher B ^a   Theroux, Pierre ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g KERCKHOFF HEART CENTER   (Germany)

^h MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Inflammation; Myocardial infarction; Prediction models

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; PEXELIZUMAB; PLACEBO; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART FAILURE; HEART RATE; HUMAN; HYPERTENSION; INFLAMMATION; INTEGRATED DISCRIMINATION IMPROVEMENT; MAJOR CLINICAL STUDY; MALE; NET RECLASSIFICATION IMPROVEMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RISK FACTOR; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CANADA; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; EPIDEMIOLOGY; FOLLOW UP; GERMANY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SHOCK, CARDIOGENIC; SWEDEN; TRENDS; UNITED STATES;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CANADA; CAUSE OF DEATH; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SHOCK, CARDIOGENIC; SINGLE-CHAIN ANTIBODIES; SWEDEN; UNITED STATES;

EID: 84885605839     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.004     Document Type: Article

References (38)

1. A. Herskowitz, S. Choi, A.A. Ansari, and S. Wesselingh Cytokine mRNA expression in postischemic/reperfused myocardium Am J Pathol 146 1995 419 428
2. G. Pannitteri, B. Marino, P.P. Campa, R. Martucci, U. Testa, and C. Peschle Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction Am J Cardiol 80 1997 622 625
3. D.A. Smith, S.D. Irving, J. Sheldon, D. Cole, and J.C. Kaski Serum levels of the antiinflammatory cytokine Interleukin-10 are decreased in patients with unstable angina Circulation 104 2001 746 749
4. A. Deten, H.C. Volz, W. Briest, and H.-G. Zimmer Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats Cardiovasc Res 55 2002 329 340
5. M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory cytokines and postmyocardial infarction remodeling Circ Res 94 2004 1543 1553
6. K. Koten, S. Hirohata, and T. Miyoshi Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size Clin Biochem 41 2008 30 37
7. L.M. Biasucci, G. Liuzzo, and G. Fantuzzi Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Circulation 99 1999 2079 2084
8. C. Heeschen, S. Dimmeler, and C.W. Hamm Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes Circulation 107 2003 2109 2114
9. T. Kilic, D. Ural, and E. Ural Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome Heart 92 2006 1041 1046
10. K.W. Lee, G.Y.H. Lip, M. Tayebjee, W. Foster, and A.D. Blann Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes Blood 105 2005 526 532
11. J.L. Mega, D.A. Morrow, and J.A. De Lemos B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy J Am Coll Cardiol 44 2004 335 339
12. P.M. Ridker, N. Rifai, M. Pfeffer, F. Sacks, S. Lepage, and E. Braunwald Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction Circulation 101 2000 2149 2153
13. P. Theroux, P.W. Armstrong, and K.W. Mahaffey Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Eur Heart J 26 2005 1964 1970
14. M. Valgimigli, C. Ceconi, and P. Malagutti Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study Circulation 111 2005 863 870
15. A.L. Pasqui, M. Di Renzo, and G. Bova Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes Clin Exp Med 6 2006 38 44
16. P. Damman, M.A.M. Beijk, and W.J. Kuijt Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction J Am Coll Cardiol 57 2011 29 36
17. S.Q. Khan, H. Narayan, and K.H. Ng N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome Clin Sci 117 2009 31 39
18. P.W. Armstrong, P.X. Adams, and H.R. Al-Khalidi Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Am Heart J 149 2005 402 407
19. The APEX AMI Investigators Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention JAMA 297 2007 43 51
20. K.W. Mahaffey, C.J. Reist, and Y. Fu Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library Contemp Clin Trials 29 2008 887 895
21. M.J. Pencina, R.B. D' Agostino, and R.S. Vasan Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172
22. J. Tan, Q. Hua, J. Gao, and Z.X. Fan Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction Clin Cardiol 31 2008 413 418
23. X. Wang, T.-L. Yue, E.H. Ohlstein, C.-P. Sung, and G.Z. Feuerstein Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response J Biol Chem 271 1996 24286 24293
24. N.G. Frangogiannis, L.H. Mendoza, M. Lewallen, L.H. Michael, and C.W. Smith Eentman. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis FASEB J 15 2001 1428 1430
25. D. Rothenbacher, S. Müller-Scholze, C. Herder, W. Koenig, and H. Kolb Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers Arterioscler Thromb Vasc Biol 26 2006 194 199
26. P. Wang, P. Wu, M.I. Siegel, R.W. Egan, and M.M. Billah Interleukin (IL)-10 inhibits nuclear factor B (NFB) activation in human monocytes J Biol Chem 270 1995 9558 9563
27. S. Lacraz, L.P. Nicod, R. Chicheportiche, H.G. Welgus, and J.M. Dayer IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes J Clin Invest 96 1995 2304 2310
28. C.H. Hannum, C.J. Wilcox, and W.P. Arend Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor Nature 343 1990 336 340
29. E.V. Granowitz, B.D. Clark, J. Mancilla, and C.A. Dinarello Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor J Biol Chem 266 1991 14147 14150
30. E. Granowitz, B. Clark, E. Vannier, M. Callahan, and C. Dinarello Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes Blood 79 1992 2356 2363
31. G. Patti, S. Mega, and V. Pasceri Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction Clin Cardiol 28 2005 193 196
32. M. Shibata, S. Endo, and K. Inada Elevated plasma levels of interleukin-1 receptor antagonist and Interleukin-10 in patients with acute myocardial infarction J Interferon Cytokine Res 17 1997 145 150
33. S. Orn, C. Manhenke, and T. Ueland C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction Eur Heart J 30 2009 1180 1186
34. A. Stebbins, R.H. Mehta, and P.W. Armstrong A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention/clinical perspective Circ Cardiovasc Interv 3 2010 414 422
35. S. Addala, C.L. Grines, and S.R. Dixon Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score) Am J Cardiol 93 2004 629 632
36. G. De Luca, H. Suryapranata, and A.W.J. van't Hof Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty Circulation 109 2004 2737 2743
37. A. Halkin, M. Singh, and E. Nikolsky Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the Cadillac risk score J Am Coll Cardiol 45 2005 1397 1405
38. R.H. Mehta, W.W. O'Neill, and K.J. Harjai Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions Am J Cardiol 97 2006 817 822